2026/08/14 Alnylam Pharmaceuticals (ALNY): From Pent-Up Demand to Normalized Growth—Re-evaluating Operating Leverage and Valuation After the Guidance Adjustment
Previous Essay Context: 2026/05/10 Alnylam Pharmaceuticals (ALNY): New Cardiomyopathy Drug & RNAi Technology Platform 1. What Happened: Guidance Reset Triggers Valuation Adjustment In my essay dated May 10, 2026, I highlighted that the sell-off across the U.S. healthcare sector was primarily a liquidity-driven event rather